fda approves first oral glp-1 obesity drug august 14 2025 A Pill to Fight Is on the Verge of Approval Alarming rise in weight loss

Retatrutide is currently in Phase 3 clinical trials and is not yet approved by regulators for public use

The first cardiovascular study of NNMT enzyme inhibition in a heart failure with preserved ejection fraction (HFpEF) mouse model demonstrated that treatment markedly reduced 1-MNA (by 77.1%), 2PY (by 66.2%), and 4PY (by 71.1%) in cardiac tissue, while improving cardiac function, enhancing global longitudinal strain, reversing peak longitudinal strain rate, and significantly reducing left ventricular hypertrophy and fibrosis

Medical Records and Continuity of Care Free AI consultations should provide a summary or visit record that patients can save or share with their primary care physician

Li R, Wan X, Takala TM, Saris PEJ (2021) Heterologous expression of the Leuconostoc bacteriocin leucocin C in probiotic yeast Saccharomyces boulardii